Mechanisms of allergy and clinical immunology
Proteome analysis of mast cell releasates reveals a role for chymase in the regulation of coagulation factor XIIIA levels via proteolytic degradation

https://doi.org/10.1016/j.jaci.2016.03.051Get rights and content

Background

Mast cells are significantly involved in IgE-mediated allergic reactions; however, their roles in health and disease are incompletely understood.

Objective

We aimed to define the proteome contained in mast cell releasates on activation to better understand the factors secreted by mast cells that are relevant to the contribution of mast cells in diseases.

Methods

Bone marrow–derived cultured mast cells (BMCMCs) and peritoneal cell–derived mast cells were used as “surrogates” for mucosal and connective tissue mast cells, respectively, and their releasate proteomes were analyzed by mass spectrometry.

Results

Our studies showed that BMCMCs and peritoneal cell–derived mast cells produced substantially different releasates following IgE-mediated activation. Moreover, we observed that the transglutaminase coagulation factor XIIIA (FXIIIA) was one of the most abundant proteins contained in the BMCMC releasates. Mast cell–deficient mice exhibited increased FXIIIA plasma and activity levels as well as reduced bleeding times, indicating that mast cells are more efficient in their ability to downregulate FXIIIA than in contributing to its amounts and functions in homeostatic conditions. We found that human chymase and mouse mast cell protease-4 (the mouse homologue of human chymase) had the ability to reduce FXIIIA levels and function via proteolytic degradation. Moreover, we found that chymase deficiency led to increased FXIIIA amounts and activity, as well as reduced bleeding times in homeostatic conditions and during sepsis.

Conclusions

Our study indicates that the mast cell protease content can shape its releasate proteome. Moreover, we found that chymase plays an important role in the regulation of FXIIIA via proteolytic degradation.

Section snippets

Methods

For detailed methods, including the mice used, experimental protocols and procedures, and statistical analysis, please see the Methods section in this article's Online Repository at www.jacionline.org.

Proteome profiling of mast cell releasates

To define the BMCMC and PCMC releasates following IgE-mediated activation, we used a mass spectrometry shotgun proteomics approach. Specifically, IgE-2, 4-dinitrophenyl–sensitized BMCMCs and PCMCs were stimulated with 2, 4-dinitrophenyl-human serum albumin antigen for 6 hours. Then, the supernatants were collected, concentrated, and subjected to LC-MS/MS to identify the IgE-mediated differentially produced proteins from these mast cells (Fig 1, A). We identified 91 proteins that were unique to

Discussion

Accumulating in vitro and in vivo evidence indicates that mast cell functions may be much broader than their well-defined contribution to IgE-associated immune responses. In this study, we characterized mast cell releasates to further understand the contribution of mast cells to health and disease. For this purpose, we used proteomics as an unbiased approach to characterize mast cell secretomes. Previous studies used mass spectrometry analysis to dissect signaling pathways that are involved in

References (46)

  • A. Roy et al.

    Mast cell chymase degrades the alarmins heat shock protein 70, biglycan, HMGB1, and interleukin-33 (IL-33) and limits danger-induced inflammation

    J Biol Chem

    (2014)
  • Y. Ge et al.

    Independent influence of strain difference and mi transcription factor on the expression of mouse mast cell chymases

    Am J Pathol

    (2001)
  • S. Zeerleder et al.

    Factor XIII in severe sepsis and septic shock

    Thromb Res

    (2007)
  • R.O. de Castro et al.

    Once phosphorylated, tyrosines in carboxyl terminus of protein-tyrosine kinase Syk interact with signaling proteins, including TULA-2, a negative regulator of mast cell degranulation

    J Biol Chem

    (2012)
  • Y. Bounab et al.

    Proteomic analysis of the SH2 domain-containing leukocyte protein of 76 kDa (SLP76) interactome in resting and activated primary mast cells [corrected]

    Mol Cell Proteomics

    (2013)
  • Y.M. Lee et al.

    Alteration of protease expression phenotype of mouse peritoneal mast cells by changing the microenvironment as demonstrated by in situ hybridization histochemistry

    Am J Pathol

    (1998)
  • K. Griffin et al.

    Use of a novel floxed mouse to characterise the cellular source of plasma coagulation FXIII-A

    Lancet

    (2015)
  • K.N. Patel et al.

    Polymicrobial sepsis and endotoxemia promote microvascular thrombosis via distinct mechanisms

    J Thromb Haemost

    (2010)
  • A. Jayo et al.

    Possible role for cellular FXIII in monocyte-derived dendritic cell motility

    Eur J Cell Biol

    (2009)
  • T.G. Loof et al.

    Coagulation, an ancestral serine protease cascade, exerts a novel function in early immune defense

    Blood

    (2011)
  • K. Stankovic et al.

    Systemic mastocytosis: predictable factors of poor prognosis present at the onset of the disease

    Eur J Intern Med

    (2005)
  • A. Prieto-Garcia et al.

    Mast cell restricted mouse and human tryptase.heparin complexes hinder thrombin-induced coagulation of plasma and the generation of fibrin by proteolytically destroying fibrinogen

    J Biol Chem

    (2012)
  • T. Takabayashi et al.

    Glandular mast cells with distinct phenotype are highly elevated in chronic rhinosinusitis with nasal polyps

    J Allergy Clin Immunol

    (2012)
  • Cited by (22)

    • Neuron‒Mast Cell Cross-Talk in the Skin

      2022, Journal of Investigative Dermatology
      Citation Excerpt :

      The first phase of crosslinking occurring within minutes of antigen encounter is characterized by the release of a heterogeneous population of preformed proteins and newly synthesized lipids (Reber et al., 2017). MCs release histamine; serotonin; cytokines; and proteases such as chymase, tryptase, and β-hexosaminidase as well as a vast array of other proteins highlighted by recent proteomics studies (Shubin et al., 2017; Starkl et al., 2020a). Degranulation products perform a variety of functions, including direct inhibition of bacterial growth, cleavage of zymogenic alarmins into biologically active forms, and directing neutrophils from the bloodstream to the tissue (Dudeck et al., 2021; Lefrançais et al., 2014; Starkl et al., 2020b).

    • Distinct 3-disulfide-bonded isomers of tridegin differentially inhibit coagulation factor XIIIa: The influence of structural stability on bioactivity

      2020, European Journal of Medicinal Chemistry
      Citation Excerpt :

      Unlike all other enzymatically active blood coagulation factors, which are serine proteases, FXIIIa is a transglutaminase that crosslinks glutamine and lysine residues of proteins via isopeptide bonds [3]. Furthermore, FXIIIa plays a crucial role in wound healing and is linked to a plethora of different physiological processes like angiogenesis, bone biology [4], immunological processes [5,6], energy metabolism [7], and pregnancy [8]. FXIII occurs in two different forms: The cellular FXIII (cFXIII) is composed of an A2 homodimer, whereas an A2B2 hetero-tetramer constitutes the plasma FXIII (pFXIII) [3].

    • Human Mast Cell Proteome Reveals Unique Lineage, Putative Functions, and Structural Basis for Cell Ablation

      2020, Immunity
      Citation Excerpt :

      To aid future studies into mast cell functions, comprehensive proteome data are a valuable resource. Proteome analyses of mast cells have been previously reported for proteins released from mouse mast cells (Shubin et al., 2017), for human short-term cultured skin mast cells (Gschwandtner et al., 2017), for phosphoproteins (Cao et al., 2007), and for lipid rafts (Freitas Filho et al., 2019) in cultured rodent mast cells. Here, we isolated primary human connective tissue mast cells from skin and fat from healthy individuals and analyzed the mast cell proteome by quantitative mass spectrometry.

    • Genome-wide Analyses of Chromatin State in Human Mast Cells Reveal Molecular Drivers and Mediators of Allergic and Inflammatory Diseases

      2019, Immunity
      Citation Excerpt :

      To investigate some of the identified candidate genes, we focused on FGL2. MCs release numerous soluble mediators, including proteases, growth factors, cytokines, and chemokines (Shubin et al., 2017). Our screen identified FGL2, which in its soluble form is mainly linked to Tregs and has suppressor activities against Th1 and Th17 cells, but not against Th2 cells (Joller et al., 2014).

    • Peripheral serotonin causes dengue virus-induced thrombocytopenia through 5HT<inf>2</inf> receptors

      2019, Blood
      Citation Excerpt :

      Although we observe that serotonin is specifically important for DENV-induced platelet activation, MCs make other products that influence hemostasis. Chymase, a MC-specific protease, can prolong bleeding time by affecting the coagulation cascade,81 but is not required for DENV-induced thrombocytopenia, as antagonism of serotonin receptors or specific ablation of MC-serotonin synthase are sufficient to block thrombocytopenia. MC-stabilizing drugs, which can also restrict thrombocytopenia during DENV infection, are commercially available, are used in the treatment of asthma, and are currently being tested for treatment of dengue vascular leakage.

    View all citing articles on Scopus

    Research for this work was supported by grants for A.M.P. from the National Institutes of Health (NIH) (grant no. HL113351-01) and the American Heart Association (grant no. 12GRNT9680021), for R.G.J. from the NIH (grant no. 5R00HL103768-04), and for N.J.S. by a fellowship from the American Association of Immunologists (2015 AAI Careers in Immunology Fellowship). N.J.W. is supported, in part, by the National Center for Advancing Translational Sciences (grant no. KL2 TR000421), a component of the NIH. S.R.R. was supported by the Parker B. Francis Fellowship. M.A. was supported by the Swedish Research Council. This work is supported in part by the University of Washington's Proteomics Resource (grant no. UWPR95794).

    Disclosure of potential conflict of interest: N. J. Shubin declares a grant from the American Academy of Immunologists. M. Abrink declares a grant from the Swedish Research Council. N. J. White declares grants/grants pending from the National Institutes of Health (NIH) and the US Department of Defense and is a board member, has provided consultancy to, and holds stock with Stasys Medical Corp. S. R. Reeves declares grants/grants pending from Parker B. Francis Foundation and the National Heart Lung and Blood Institute (NHLBI). R. G. James declares a grant from the NIH, NHLBI. T. Vaisar declares a grant from the NIH. A. M. Piliponsky declares grants from the NIH and the American Heart Association. The rest of the authors declare that they have no relevant conflicts of interest.

    View full text